Aarti Pharmalabs Q1 FY27: Revenue ₹535.8cr, PAT ₹76.1cr

Key takeaway from Q1 FY27

Aarti Pharmalabs Ltd reported a sharp year-on-year improvement in its Q1 FY27 financials, with revenue growth of about 39% to 42% and a higher profit base across standalone and consolidated reporting. The quarter ended June 30, 2026, and the company later held its earnings conference call on August 10, 2026. Alongside the financial update, the company formally notified stock exchanges that the audio recording of the earnings call has been made available on its official website. For investors, the combination of higher operating scale and steady margins is the central data point from the quarter.

Earnings call: audio recording made available

Aarti Pharmalabs informed exchanges about the availability of the audio recording for its Q1 FY27 earnings conference call. The recording covers management commentary on the financial results for the quarter ended June 30, 2026, and includes responses to analyst questions. The company said the audio is accessible on its official website, enabling shareholders and other interested parties to review the discussion in full.

Standalone performance: revenue, EBITDA, PAT

On a standalone basis, operational revenue in Q1 FY27 rose to ₹534.6 crore, compared with ₹375.3 crore in Q1 FY26, translating to 42.4% year-on-year growth. EBITDA increased to ₹132.7 crore from ₹95.1 crore, up 39.5% year-on-year. The EBITDA margin stood at 24.82%, down 52 basis points from 25.34% a year ago. Profit after tax (PAT) rose to ₹71.3 crore from ₹47.8 crore, a 49.2% year-on-year increase. Standalone PAT margin improved to 13.34% from 12.74%, up 60 basis points.

Consolidated performance: revenue, profit and margins

On a consolidated basis, operational revenue for Q1 FY27 came in at ₹535.8 crore versus ₹386.2 crore in Q1 FY26, a 38.7% year-on-year increase. Consolidated EBITDA was ₹132.6 crore compared with ₹95.2 crore, up 39.3% year-on-year. EBITDA margin was 24.75%, slightly higher by 10 basis points compared with 24.65% in the prior-year quarter. Consolidated PAT was ₹76.1 crore versus ₹46.0 crore in Q1 FY26, a 65.4% year-on-year rise. Consolidated PAT margin expanded to 14.20% from 11.91%, up 229 basis points.

What management highlighted on the call

As per the earnings call transcript, management summarised the quarter with topline at about ₹535 crore compared with ₹375 crore a year earlier, reflecting 42% year-on-year growth on that comparison set. EBITDA was stated at about ₹133 crore versus ₹95 crore, up 40% year-on-year, while PAT was about ₹71 crore versus ₹48 crore, up 49% year-on-year. These figures align closely with the standalone operational metrics shared in the quarter’s performance table, with small differences attributable to rounding and presentation.

Profit before tax, JV contribution and other income

The transcript details additional consolidated line items that help explain profit movement. Profit before tax (PBT) was reported at ₹101.06 crore in Q1 FY27, up 66.2% year-on-year and 23.7% quarter-on-quarter. This included a share of profit from joint ventures of ₹7.41 crore in Q1 FY27, compared with a loss of ₹1.80 crore in the year-ago quarter. Other income declined 41.3% year-on-year to ₹0.45 crore.

Cost trends reported for the quarter

On the consolidated cost side, total expenses were reported at ₹442.59 crore in Q1 FY27, up 36.5% year-on-year but down 14.0% quarter-on-quarter. Cost of materials consumed rose 31.6% year-on-year to ₹251.87 crore. The relationship between expense growth and revenue growth matters for interpreting margins, and the company’s reported EBITDA margins around 24.7% to 24.8% show that operating profitability stayed broadly stable despite cost inflation in key inputs.

Snapshot table: Q1 FY27 vs Q1 FY26

All figures below are presented in ₹ crore (converted from ₹ million where applicable) and reflect the company’s stated standalone and consolidated metrics.

Market impact: what the numbers signal

The quarter’s key signal is that growth was not limited to revenue, as EBITDA and PAT also rose strongly year-on-year. On standalone numbers, revenue growth of 42.4% was matched by a 39.5% increase in EBITDA, while PAT rose 49.2%, indicating better conversion of operating profit into net profit. On consolidated numbers, PAT growth at 65.4% outpaced revenue growth at 38.7%, supported by higher PAT margin (14.20%) compared with last year (11.91%). Investors tracking operating resilience would typically focus on the EBITDA margin staying near 25% even as material consumption costs increased to ₹251.87 crore.

Analysis: why the earnings call access matters

For public market investors, the availability of the earnings call recording is a practical governance and disclosure input. It allows shareholders to review how management explains quarter-on-quarter movements such as the 8.0% decline in consolidated revenue from operations on a QoQ basis (as stated in the transcript), alongside the reported 24.6% QoQ increase in consolidated net profit. It also provides context on non-operating drivers, including the joint venture profit share of ₹7.41 crore, which swung from a loss in the year-ago quarter. Given the close alignment between the transcript’s rounded numbers (₹535 crore revenue, ₹133 crore EBITDA, ₹71 crore PAT) and the detailed standalone table metrics, investors can cross-check performance across different reporting cuts.

Conclusion

Aarti Pharmalabs’ Q1 FY27 showed strong year-on-year expansion in operational revenue to about ₹535 crore, EBITDA to about ₹133 crore, and profit, with consolidated PAT reported at ₹76.1 crore and improving margins. The company has also made the Q1 FY27 earnings call audio available on its website after notifying exchanges, giving investors direct access to management commentary for the quarter ended June 30, 2026.